Upadacitinib: One More Option in the Treatment of Patients with Rheumatoid Arthritis and Crohn's Disease

Arthritis and IBD are conditions that can occur in the same patient simultaneously. The complexity in managing these cases lies in detecting the signs and symptoms that point to the onset of the disease at an early stage, and in choosing an appropriate course of treatment to control the joint and intestinal aspects at the same time. In recent times, a new class of drugs has been added to the treatment options: JAK inhibitors (JAKi), of which Upadacitinib is one. Being able to manage and follow up with these patients in joint gastro-rheumatology outpatient clinics, where professionals from both disciplines are able to follow these cases appropriately, avoiding delays in diagnosis andtreatment, is also important